Patent · US Active

Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells

US11464806B2 · kind B2 · utility

1Cited by

0References

20Claims

0Family size

Assignee

JUNCTUCELL BIOMED MANUFACTURING GMBH · DE

Inventors

Christine Günther · Munich, DE
Stefanos Theoharis · Munich, DE
Felix Hermann · Munich, DE
Ralf Huss · Waakirchen, DE

Key dates

Filing date	Jan 28, 2020
Grant date	Oct 11, 2022
Priority date	—
Expiry date	Jul 5, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2510/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A method of treating a tumor in a subject including administering a genetically modified mesenchymal stem cell (MSC), wherein the MSC includes one or more exogenous nucleic acid molecule(s), wherein the one or more exogenous nucleic acid molecule(s) includes one or more regions encoding two or more immune response-stimulating cytokines operably linked to one or more promoters or promoter/enhancer combinations, wherein the two or more immune response-stimulating cytokines include at least IL-7, and at least one of IL-12 or IL-21.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.